We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression

Alberto Ascherio, MD, DrPH1; Kassandra L. Munger, ScD1; Rick White, MSc2; Karl Köchert, PhD3; Kelly Claire Simon, ScD1; Chris H. Polman, MD4; Mark S. Freedman, MD5; Hans-Peter Hartung, MD6; David H. Miller, MD7; Xavier Montalbán, MD8; Gilles Edan, MD9; Frederik Barkhof, MD4; Dirk Pleimes, MD10; Ernst-Wilhelm Radü, MD11; Rupert Sandbrink, MD3,6; Ludwig Kappos, MD11; Christoph Pohl, MD3,12
[+] Author Affiliations
1Harvard School of Public Health, Boston, Massachusetts
2University of British Columbia, Vancouver, Canada
3Bayer HealthCare, Berlin, Germany
4VU University Medical Center, Amsterdam, the Netherlands
5Ottawa Hospital Research Institute, Ottawa, Canada
6Heinrich-Heine Universität, Düsseldorf, Germany
7University College London Institute of Neurology, London, England
8Hospital Universitari Vall d’Hebron, Barcelona, Spain
9CHU-Hôpital Pontchaillou, Rennes, France
10Bayer HealthCare Pharmaceuticals, Montville, New Jersey
11University Hospital Basel, Basel, Switzerland
12Department of Neurology, University Hospital of Bonn, Bonn, Germany
JAMA Neurol. 2014;71(3):306-314. doi:10.1001/jamaneurol.2013.5993.
Text Size: A A A
Published online

Importance  It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes.

Objectives  To determine whether serum concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of MS (clinically isolated syndrome).

Design, Setting, and Participants  The Betaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment study was a randomized trial originally designed to evaluate the impact of early vs delayed interferon beta-1b treatment in patients with clinically isolated syndrome. Serum 25(OH)D concentrations were measured at baseline and 6, 12, and 24 months. A total of 465 of the 468 patients randomized had at least 1 25(OH)D measurement, and 334 patients had them at both the 6- and 12-month (seasonally asynchronous) measurements. Patients were followed up for 5 years clinically and by magnetic resonance imaging.

Main Outcomes and Measures  New active lesions, increased T2 lesion volume, and brain volume on magnetic resonance imaging, as well as MS relapses and disability (Expanded Disability Status Scale score).

Results  Higher 25(OH)D levels predicted reduced MS activity and a slower rate of progression. A 50-nmol/L (20-ng/mL) increment in average serum 25(OH)D levels within the first 12 months predicted a 57% lower rate of new active lesions (P < .001), 57% lower relapse rate (P = .03), 25% lower yearly increase in T2 lesion volume (P < .001), and 0.41% lower yearly loss in brain volume (P = .07) from months 12 to 60. Similar associations were found between 25(OH)D measured up to 12 months and MS activity or progression from months 24 to 60. In analyses using dichotomous 25(OH)D levels, values greater than or equal to 50 nmol/L (20 ng/mL) at up to 12 months predicted lower disability (Expanded Disability Status Scale score, −0.17; P = .004) during the subsequent 4 years.

Conclusions and Relevance  Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.

Figures in this Article
Sign in to download this free article PDF

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.
Multiple Sclerosis Outcomes According to Dichotomous Serum 25-Hydroxyvitamin D Levels

Analyses are based on patients with month 6 and month 12 measurements of 25-hydroxyvitamin D. Group comparisons are adjusted for age, sex, treatment, time of follow-up, and T2 lesion score at baseline. The graphs show the probability of conversion to clinically definite multiple sclerosis (CDMS) after 12 months (A); the cumulative number of new active lesions on brain magnetic resonance imaging (B); the percentage change in T2 lesion volume from year 1 to year 5 on brain magnetic resonance imaging (C); and percentage change in brain volume from year 1 to year 5 (D). The error bars indicate the standard error of the mean (SEM).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Magnetic Resonance Imaging Evidence of Multiple Sclerosis Activity and Progression

A, Rate ratio of new active lesions on brain magnetic resonance imaging up to year 5. B, Change of T2 lesion volume on brain magnetic resonance imaging from year 1 to year 5 by quintiles of serum 25-hydroxyvitamin D (25[OH]D). C, Annualized change in Expanded Disability Status Scale (EDSS) score from 6 months to year 5 by quintiles of serum 25(OH)D. Analyses as in Figure 1. The error bars indicate 95% CIs, with the lowest quintile used as reference.aP = .02.bP = .008.cP = .001.dP = .004.eP = .03.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 18

Sign in to download this free article PDF

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections